Dermapharm Holding SE provided earnings guidance for the year 2023. The positive performance in the first half of 2023 laid a good foundation for the further course of the business. The Board of Management currently expects to achieve both revenues at the upper end of the published guidance range of EUR 1,080 million to EUR 1,110 million.